Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Cash & Current Investments (2018 - 2021)

Historic Cash & Current Investments for Black Diamond Therapeutics (BDTX) over the last 4 years, with Q3 2021 value amounting to $235.0 million.

  • Black Diamond Therapeutics' Cash & Current Investments fell 2944.23% to $235.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was $235.0 million, marking a year-over-year decrease of 2944.23%. This contributed to the annual value of $315.1 million for FY2020, which is 10370.8% up from last year.
  • Latest data reveals that Black Diamond Therapeutics reported Cash & Current Investments of $235.0 million as of Q3 2021, which was down 2944.23% from $263.5 million recorded in Q2 2021.
  • Over the past 5 years, Black Diamond Therapeutics' Cash & Current Investments peaked at $357.2 million during Q1 2020, and registered a low of $39.6 million during Q2 2019.
  • Moreover, its 4-year median value for Cash & Current Investments was $219.7 million (2020), whereas its average is $197.3 million.
  • As far as peak fluctuations go, Black Diamond Therapeutics' Cash & Current Investments surged by 69878.12% in 2020, and later crashed by 2944.23% in 2021.
  • Black Diamond Therapeutics' Cash & Current Investments (Quarter) stood at $51.7 million in 2018, then surged by 199.39% to $154.7 million in 2019, then skyrocketed by 103.71% to $315.1 million in 2020, then decreased by 25.41% to $235.0 million in 2021.
  • Its Cash & Current Investments was $235.0 million in Q3 2021, compared to $263.5 million in Q2 2021 and $290.1 million in Q1 2021.